These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
328 related items for PubMed ID: 20720012
1. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. Zheng YL, Amin ND, Hu YF, Rudrabhatla P, Shukla V, Kanungo J, Kesavapany S, Grant P, Albers W, Pant HC. J Biol Chem; 2010 Oct 29; 285(44):34202-12. PubMed ID: 20720012 [Abstract] [Full Text] [Related]
2. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Zheng YL, Li BS, Amin ND, Albers W, Pant HC. Eur J Biochem; 2002 Sep 29; 269(18):4427-34. PubMed ID: 12230554 [Abstract] [Full Text] [Related]
3. AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain. Xu M, Huang Y, Song P, Huang Y, Huang W, Zhang HT, Hu Y. J Alzheimers Dis; 2019 Sep 29; 70(2):573-585. PubMed ID: 31256130 [Abstract] [Full Text] [Related]
4. p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity. Zhang L, Liu W, Szumlinski KK, Lew J. Proc Natl Acad Sci U S A; 2012 Dec 04; 109(49):20041-6. PubMed ID: 23151508 [Abstract] [Full Text] [Related]
5. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases. Binukumar BK, Pelech SL, Sutter C, Shukla V, Amin ND, Grant P, Bhaskar M, Skuntz S, Steiner J, Pant HC. J Alzheimers Dis; 2016 Sep 06; 54(2):525-33. PubMed ID: 27567857 [Abstract] [Full Text] [Related]
6. Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein. Binukumar BK, Shukla V, Amin ND, Bhaskar M, Skuntz S, Steiner J, Winkler D, Pelech SL, Pant HC. J Alzheimers Dis; 2015 Sep 06; 48(4):1009-17. PubMed ID: 26444778 [Abstract] [Full Text] [Related]
7. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttilä T. Biochem Biophys Res Commun; 2002 Nov 15; 298(5):693-8. PubMed ID: 12419309 [Abstract] [Full Text] [Related]
8. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. Zheng YL, Kesavapany S, Gravell M, Hamilton RS, Schubert M, Amin N, Albers W, Grant P, Pant HC. EMBO J; 2005 Jan 12; 24(1):209-20. PubMed ID: 15592431 [Abstract] [Full Text] [Related]
9. The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35. Amin ND, Zheng Y, Bk B, Shukla V, Skuntz S, Grant P, Steiner J, Bhaskar M, Pant HC. Mol Biol Cell; 2016 Nov 01; 27(21):3221-3232. PubMed ID: 27630261 [Abstract] [Full Text] [Related]
10. TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity. Binukumar BK, Zheng YL, Shukla V, Amin ND, Grant P, Pant HC. J Alzheimers Dis; 2014 Nov 01; 39(4):899-909. PubMed ID: 24326517 [Abstract] [Full Text] [Related]
11. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5. Kesavapany S, Zheng YL, Amin N, Pant HC. Biotechnol J; 2007 Aug 01; 2(8):978-87. PubMed ID: 17526058 [Abstract] [Full Text] [Related]
12. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats. Tan X, Chen Y, Li J, Li X, Miao Z, Xin N, Zhu J, Ge W, Feng Y, Xu X. Neuroscience; 2015 Apr 02; 290():552-60. PubMed ID: 25665755 [Abstract] [Full Text] [Related]
13. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. Li G, Faibushevich A, Turunen BJ, Yoon SO, Georg G, Michaelis ML, Dobrowsky RT. J Neurochem; 2003 Jan 02; 84(2):347-62. PubMed ID: 12558997 [Abstract] [Full Text] [Related]
14. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation. Sun LH, Ban T, Liu CD, Chen QX, Wang X, Yan ML, Hu XL, Su XL, Bao YN, Sun LL, Zhao LJ, Pei SC, Jiang XM, Zong DK, Ai J. J Neurochem; 2015 Sep 02; 134(6):1139-51. PubMed ID: 26118667 [Abstract] [Full Text] [Related]
15. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide. Kesavapany S, Li BS, Amin N, Zheng YL, Grant P, Pant HC. Biochim Biophys Acta; 2004 Mar 11; 1697(1-2):143-53. PubMed ID: 15023357 [Abstract] [Full Text] [Related]
16. Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore. Cardone A, Brady M, Sriram R, Pant HC, Hassan SA. J Comput Aided Mol Des; 2016 Jun 11; 30(6):513-21. PubMed ID: 27387995 [Abstract] [Full Text] [Related]
17. Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation. Corbel C, Zhang B, Le Parc A, Baratte B, Colas P, Couturier C, Kosik KS, Landrieu I, Le Tilly V, Bach S. Chem Biol; 2015 Apr 23; 22(4):472-482. PubMed ID: 25865311 [Abstract] [Full Text] [Related]
18. A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes. Pao PC, Seo J, Lee A, Kritskiy O, Patnaik D, Penney J, Raju RM, Geigenmuller U, Silva MC, Lucente DE, Gusella JF, Dickerson BC, Loon A, Yu MX, Bula M, Yu M, Haggarty SJ, Tsai LH. Proc Natl Acad Sci U S A; 2023 Apr 18; 120(16):e2217864120. PubMed ID: 37043533 [Abstract] [Full Text] [Related]
19. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Hisanaga S, Saito T. Neurosignals; 2003 Apr 18; 12(4-5):221-9. PubMed ID: 14673209 [Abstract] [Full Text] [Related]
20. Changes in the prefrontal cortex after the hippocampus was injected with Aβ25-35 via the P35/P25-CDK5-Tau hyperphosphorylation signaling pathway. Wang Y, Sheng H, Zhao J, Guo L, Liu J, Xu J, Liu Q, Huang J, Jiang R, Gan S, Qiu G, Lu W, Xu S, Zhu S. Neurosci Lett; 2021 Jan 10; 741():135453. PubMed ID: 33186609 [Abstract] [Full Text] [Related] Page: [Next] [New Search]